Her har dere litt om ONCOS-214 abstractet som kommer neste uke 
Next Generation ONCOS Double Transgene Oncolytic Adenovirus Exhibits Enhanced Anticancer Effect in Melanoma Lukasz Kuryk1,2, Anne-Sophie Moller3 1 Clinical Science, Targovax Oy, Helsinki, Finland,2 Department of Virology, National Institute of Public Health - National Institute of Hygiene, Warsaw, Poland,3 Clinical Science, Targovax ASA, Oslo, Norway
Oncolytic virotherapy is a promising and fast emerging anti-cancer strategy. To date, herpes virus: Talimogene laherparepvec is the only FDA approved oncolytic virus (OV), however, many other types of OVs are showing promising results in clinical studies. One example is chimeric oncolytic adenovirus ONCOS-102, expressing GM-CSF as a transgene, which recently reported 33% ORR in advanced antiPD1 refractory melanoma phase I study (NCT03003676).
Genetically modified OVs can be armed with different co-stimulatory molecules in order to boost the anti-tumour immune responses. Based on the ONCOS-102 backbone, we have engineered next generation ONCOS virus, ONCOS-214, expressing novel double transgenes designed to enhance apoptosis of the cancer cells, leading to increase the release of tumour antigens and thereby enhance cross presentation of tumour antigens and priming of cancer specific T cells.
The oncolytic properties of ONCOS-214 were confirmed in 4 melanoma cell lines in vitro, demonstrating robust cell lysis and anti-cancer properties. Anti-cancer effects of the viruses were also assessed in i) immunodeficient xenograft and ii) humanized xenograft mouse models to further understand the anti-cancer and immune stimulatory potency of the constructs. Tumor growth analysis showed that the double transgene virus ONCOS-214 had the most profound antitumor properties with a significant tumor growth reduction of the A2058 tumour compared to other treated groups in the immunodeficient mouse model. Moreover, the treatment with ONCOS-214 at different doses kept most of the tumors volume under 600 mm3 after the second round of treatment. Synergistic antitumor effect of ONCOS-214 was observed. Interestingly the treatment with ONCOS-214 resulted in highest infiltration of CD4+ T cells.
